AUS
NZ
UK
CA
USA
IND
Highlights
- AFT Pharmaceuticals reported strong profit growth supported by rising revenue.
- Expansion across international healthcare markets continued gaining traction.
- Management expects further earnings and sales momentum during the current financial year.
AFT Pharmaceuticals Ltd (ASX:AFP) shares moved higher after the healthcare company delivered a strong full-year result driven by expanding sales across both Australasian and international operations.
The company highlighted broad-based growth across prescription medicines, consumer healthcare products, and international distribution channels as major contributors to the result.
Revenue Growth Supports Stronger Earnings
Management reported a sharp improvement in profit alongside solid revenue expansion during the financial year.
The result reflected continued demand across core healthcare categories as well as growing contributions from newer international markets.
The company also announced a dividend payment while outlining expectations for additional earnings growth during the current reporting period.
Australasian Operations Continue Driving Performance
Australia and New Zealand remained the company’s core earnings base.
Management pointed to strong performance across over-the-counter healthcare products, prescription medicines, allergy treatments, dermatology products, and eye care categories.
New product launches and ongoing portfolio expansion also supported momentum across the region.
The company described Australasian operations as continuing to provide reliable cash generation while international markets scale.
International Expansion Continues
AFT Pharmaceuticals is continuing its strategy of building healthcare distribution hubs across overseas markets that share similar regulatory and commercial structures to Australasia.
The company expanded operations across the United Kingdom, Europe, North America, and South Africa during the year.
Management indicated these regions are progressing steadily from early establishment phases toward broader commercial development.
International diversification is becoming an increasingly important part of the company’s long-term growth strategy.
Maxigesic Rollout Expands Further
One of the company’s key products, Maxigesic, continued expanding its international footprint.
The product gained broader pharmacy distribution across the United Kingdom while hospital rollout activity also progressed.
Management highlighted ongoing adoption within healthcare systems as an encouraging sign for future product demand.
The expansion of established healthcare brands into larger overseas markets may continue supporting long-term revenue growth.
European Product Pipeline Progresses
The company also reported progress tied to its injectable medicine portfolio in Europe.
Updated regulatory approvals and licensing work are supporting planned product launches across European markets.
Management expects these products to contribute more meaningfully during the current financial year as commercial rollout expands further.
This creates additional diversification alongside the company’s existing pharmaceutical and consumer healthcare portfolio.
Positive Outlook For Current Financial Year
Management issued guidance indicating expectations for further operational growth ahead.
The company is targeting higher revenue and improved operating performance as international operations continue scaling.
Expansion across multiple regions combined with new product launches appears central to the broader strategy moving forward.
Financial Position Remains Stable
The company also stated that its balance sheet remains within targeted leverage levels despite continued investment into growth initiatives.
Maintaining financial flexibility remains important for pharmaceutical businesses given the ongoing costs tied to regulatory approvals, distribution expansion, and product commercialisation.
Healthcare Demand Remains Resilient
The result also highlights the defensive characteristics often associated with healthcare businesses.
Demand for pharmaceutical products and healthcare services tends to remain relatively stable across changing economic conditions.
Companies capable of successfully scaling internationally while maintaining strong product demand may continue benefiting from long-term structural healthcare trends.
